

FROST BROWN TODD LLC

2200 PNC CENTER
201 EAST FIFTH STREET - P.O. BOX 5715
CINCINNATI, OHIO 45201-5715
(513) 651-6800
FAX NUMBER: (513) 651-6981
COMMUNICATIONS CENTER (513) 651-6775
FAX COVER SHEET

FAX RECEIVED

DEC 12 2000

GROUP 1600**OFFICIAL**

**TOTAL NUMBER OF PAGES
INCLUDING THIS SHEET**

6

TO: U.S. Patent and Trademark Office -- Attn: G.Gabel

FAX NO.: 703-308-4242

FROM: Stephen R. Albainy-Jenei

TELEPHONE NO.: 513-651-6839

DATE: 12/11/00

CONFIRM FAX SENT/RETURN ORIGINAL TO: J.Fields **EXT.:** 6974

COMMENTS

Art Unit No: 1641
Serial No: 09/167,088

THE INFORMATION CONTAINED IN THIS FAX IS INTENDED FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, ATTORNEYS' WORK PRODUCT AND/OR EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT (OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT), YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US BY COLLECT TELEPHONE.

OTHER OFFICES (FAX NUMBER)

LOUISVILLE, KY (502) 581-1087
COLUMBUS, OH (614) 464-1737
COVINGTON, KY (859) 431-2191
MIDDLETOWN, OH (513) 422-3010
NEW ALBANY, IN (812) 948-7994
NASHVILLE, TN (615) 251-5551
LEXINGTON, KY (859) 253-2990

PATENT**IN THE UNITED STATES PATENT & TRADEMARK OFFICE**

Applicant: Finkelman et al. : Paper No: 91830/625
Serial No. 09/167,088 : Group Art Unit: 1641
Filed: October 6, 1998 : Examiner: G. Gabel
For: METHODS FOR MEASURING IN VIVO CYTOKINE PRODUCTION

SUMMARY OF TELEPHONE CONFERENCE

Box Non-Fee Amendment
The Assistant Commissioner For Patents
Washington, D.C. 20231

Dear Sir:

This communication embodies the discussions in the telephonic interview on December 11, 2000, with the Examiner, Ms. Gabel in response to an Office Action mailed on September 13, 2000.

Proposed Amendments

Please rewrite Claim 1.

1. (Thrice Amended) A method of measuring the production of a secreted target analyte of interest in a human or animal, comprising the steps of:
- a. injecting the human or animal with an amount of neutralizing targeting moiety, capable of binding specifically to the target analyte, in excess of measurable quantities of target analyte;

OFFICIAL